Camelid News and Research

RSS

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

Aptamer Group Ltd and Bio-Works Technologies AB today announce that they have entered into an agreement to co-develop a new affinity resin.

From Aptamer Group 26 Aug 2021

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

A new study has been published on the bioRxiv* preprint server, which has identified and characterized two RBD-targeting neutralizing nanobodies, namely, DL4 and DL28.

23 Jul 2021

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Scientists have developed a 'nanobody' - a small fragment of a llama antibody - that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system.

22 Jul 2021

Engineering nanobodies to fight against the SARS-CoV-2 virus

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

22 Jun 2021

Nanobodies from nanomice and llamas show potent neutralizing activity against SARS-CoV-2 variants

While several COVID-19 vaccines have been approved to date, the constant evolution of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) receptor-binding domain (RBD) has challenged the efficacy of these vaccines.

11 Jun 2021

Nanobody inhalation found to be effective against COVID-19 in hamsters

In a recent paper, researchers describe an aerosolized nanobody formulation that was found to effectively block SARS-CoV-2 in Syrian hamsters.

27 May 2021

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

A team of Australian researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI), the Doherty Institute, and the Kirby Institute have identified neutralizing nanobody cocktails that block the SARS-CoV-2 virus from entering cells in pre-clinical models.

27 Apr 2021

Researchers explore an inhalable SARS-CoV-2 nanobody therapy

Even as vaccines against SARS-CoV-2 are being developed and administered at an unprecedented pace, treating this infection remains a challenge. To address this, researchers from China have used nanobodies (Nb) as a possible therapeutic approach. They reported Nb phage display libraries derived from four camels immunized with the SARS-CoV-2 spike RBD.

12 Apr 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

Tiny antibodies naturally generated by llamas can be effective against COVID-19

As the fight against COVID-19 continues, scientists have turned to an unlikely source for a potentially effective treatment: tiny antibodies naturally generated by llamas.

10 Mar 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Crystal structures of nanobodies could aid the design of COVID-19 therapies

Researchers at the National Institutes of Health in Bethesda, Maryland, have shown how certain synthetic nanobodies bind to the agent that causes coronavirus disease 2019 (COVID-19) – a development that could help inform the design of therapies.

31 Jan 2021

New publication describes DiosCURE’s multivalent single-chain antibodies to inactivate SARS-CoV-2

DiosCURE SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.

13 Jan 2021

Bispecific sybodies show potential against SARS-CoV-2

As the search for effective antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, a new study published on the preprint bioRxiv in November 2020 discusses the role of synthetic nanobodies or sybodies in neutralizing the virus by binding to its receptor-binding domain (RBD) on the spike protein.

12 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

Alpaca-derived antiviral agent neutralizes SARS-CoV-2

Researchers at Karolinska University Hospital and the University of Cape Town have identified an antibody fragment that targets the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and potently neutralizes the virus.

4 Jun 2020

Antibodies from llamas may hold cure for novel coronavirus SARS-CoV-2

As scientists across the globe race to find an effective treatment for the novel coronavirus, a team of scientists believe that a four-year-old llama named Winter may hold the key to fight the coronavirus disease (COVID-19).

7 May 2020

Researchers show how bats carry the MERS coronavirus

A University of Saskatchewan (USask) research team has uncovered how bats can carry the Middle East respiratory syndrome (MERS) coronavirus without getting sick--research that could shed light on how coronaviruses make the jump to humans and other animals.

7 May 2020